Enter multiple symbols separated by commas

Biogen Inc


  • Health Net and BP are big market movers Thursday, 2 Jul 2015 | 4:29 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Health Net Inc., up $6.51 to $71.57. The managed health care services company is being bought by Medicaid coverage provider Centene Corp. for about $6.3 billion.

  • Pfizer Inc, the largest U.S. drugmaker, for example reported more than $234.2 million in research payments and another $53.3 million in general payments. John Diliberti, a pediatric geneticist from Illinois, collected nearly $447,000 from Pfizer in consulting fees last year, the biggest single payment to an individual doctor by the drugmaker.

  • As tech stocks stall, these names may break out Wednesday, 10 Jun 2015 | 1:55 PM ET

    Technology, one of the hottest areas in the six-year bull market has hit a standstill in 2015. Here are the stocks that could buck the trend.

  • *Criminal, civil charges filed in New Jersey. Attorney Paul Fishman in New Jersey said Steven Fishoff, 58, the president of Featherwood Capital Inc in Westlake Village, California, was charged with four counts of securities fraud and one count of conspiracy. Also charged with securities fraud and conspiracy were Fishoff's brother-in-law Steven Costantin, 54,...

  • This stock is no longer in the Top 20 most held Friday, 29 May 2015 | 11:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.

  • Beat the millennials with these 9 stocks Thursday, 28 May 2015 | 10:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Nine S&P 500 stocks, including Kroger and Hanesbrands, outperform the most widely owned stocks by Millenials, USA Today reports.

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • CEOs love buying stock with your money, not own Monday, 18 May 2015 | 11:35 AM ET
    Senior exec stocks

    As CEOs buy a record amount of stock with shareholder money, they're keeping their wallets in their pockets when it comes to buying shares on their own.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • Early movers: AOL, WHR, PM, CBS, NOK & more Friday, 8 May 2015 | 7:47 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Biotech bust may be sending message about stocks Thursday, 30 Apr 2015 | 5:03 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are watching the iShares Nasdaq Biotechnology ETF for clues on whether a deeper stock market decline is on the horizon.

  • Pisani: Stay calm, despite poor end to the month Thursday, 30 Apr 2015 | 4:59 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Crowded "long" trades unwinding

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Street picks: 10 stocks ready to pop Thursday, 30 Apr 2015 | 7:00 AM ET

    More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.

  • Biogen takes on Alzheimer's Tuesday, 28 Apr 2015 | 4:29 PM ET

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • What's wrong with healthcare and biotech? Monday, 27 Apr 2015 | 3:32 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.

  • April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...